Omid Hamid, MD
Chief of Translational Research and Immuno-Oncology
The Angeles Clinic and Research Institute
Omid Hamid, MD is the Chief of Translational Research and Immuno-Oncology at The Angeles Clinic and Research Institute. He also serves as the Co-Director of the Melanoma and Phase I Programs. His areas of expertise include immunotherapy and phase I drug development.
Dr. Hamid has published extensively and has been at the forefront of the development of paradigm shifting breakthroughs, including BRAF/MEK targeted agents, AntiCTLA4, antiPD1 and PDL1 therapies. His current interests include new immunotherapeutic options for patients including bi-specific antibodies, Adoptive T cell Therapy, and oncolytic therapies, with a focus on combinatorial approaches resulting in potentially greater patient benefit. Through his leadership, The Angeles Clinic has fostered a program that combines expert clinical care with teaching and leading clinical research.
Dr. Hamid is recognized as one of the preeminent Immuno-Oncologists and melanoma specialists worldwide. He lectures extensively, both nationally and internationally. Dr. Hamid believes that fostering innovative therapies directly to the clinical trial format serves as the most effective and quickest way to ensure patients can benefit from treatment. Dr. Hamid is a member of the ASCO (American Society of Clinical Oncology), SITC (Society for Immunotherapy of Cancer), AACR (American Association for Cancer Research) and ESMO (European Society for Medical Oncology.
Sessions
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}